157 related articles for article (PubMed ID: 31118840)
1. Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population.
Alsaleh M; Barbera TA; Reeves HL; Cramp ME; Ryder S; Gabra H; Nash K; Shen YL; Holmes E; Williams R; Taylor-Robinson SD
Hepat Med; 2019; 11():47-67. PubMed ID: 31118840
[No Abstract] [Full Text] [Related]
2. Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort.
Alsaleh M; Leftley Z; Barbera TA; Koomson LK; Zabron A; Crossey MME; Reeves HL; Cramp M; Ryder S; Greer S; Prince M; Sithithaworn P; Shariff M; Khuntikeo N; Loilome W; Yongvanit P; Shen YL; Cox IJ; Williams R; Wadsworth CA; Holmes E; Nash K; Taylor-Robinson SD
J Clin Exp Hepatol; 2020; 10(1):17-29. PubMed ID: 32025163
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of the Urinary Metabolic Profile of Liver Fluke-Associated Cholangiocarcinoma.
Alsaleh M; Sithithaworn P; Khuntikeo N; Loilome W; Yongvanit P; Chamadol N; Hughes T; O'Connor T; Andrews RH; Holmes E; Taylor-Robinson SD
J Clin Exp Hepatol; 2019; 9(6):657-675. PubMed ID: 31889746
[TBL] [Abstract][Full Text] [Related]
4. Urinary Metabolic Profiling of Liver Fluke-Induced Cholangiocarcinoma-A Follow-Up Study.
Alsaleh M; Sithithaworn P; Khuntikeo N; Loilome W; Yongvanit P; Hughes T; O'Connor T; Andrews RH; Wadsworth CA; Williams R; Koomson L; Cox IJ; Holmes E; Taylor-Robinson SD
J Clin Exp Hepatol; 2023; 13(2):203-217. PubMed ID: 36950498
[TBL] [Abstract][Full Text] [Related]
5. Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls.
Zhang X; Yang Z; Shi Z; Zhu Z; Li C; Du Z; Zhang Y; Wang Z; Jiao Z; Tian X; Zhang J; Zhai W; Kan Q
J Steroid Biochem Mol Biol; 2021 Jan; 205():105775. PubMed ID: 33130021
[TBL] [Abstract][Full Text] [Related]
6. Mapping of population disparities in the cholangiocarcinoma urinary metabolome.
Alsaleh M; Leftley Z; O'Connor T; Hughes T; Barbera TA; Koomson LK; Zabron A; Reeves H; Cramp M; Ryder SD; Greer S; Prince M; Sithithaworn P; Khuntikeo N; Loilome W; Yongvanit P; Cox IJ; Williams R; Wadsworth CA; Holmes E; Nash K; Andrews R; Taylor-Robinson SD
Sci Rep; 2021 Oct; 11(1):21286. PubMed ID: 34711878
[TBL] [Abstract][Full Text] [Related]
7. Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy.
Sharif AW; Williams HR; Lampejo T; Khan SA; Bansi DS; Westaby D; Thillainayagam AV; Thomas HC; Cox IJ; Taylor-Robinson SD
HPB (Oxford); 2010 Aug; 12(6):396-402. PubMed ID: 20662790
[TBL] [Abstract][Full Text] [Related]
8. Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma.
Voigtländer T; Metzger J; Husi H; Kirstein MM; Pejchinovski M; Latosinska A; Frantzi M; Mullen W; Book T; Mischak H; Manns MP
J Biomed Sci; 2020 Jan; 27(1):13. PubMed ID: 31900160
[TBL] [Abstract][Full Text] [Related]
9. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
[TBL] [Abstract][Full Text] [Related]
10. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
[TBL] [Abstract][Full Text] [Related]
11. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
[TBL] [Abstract][Full Text] [Related]
12. Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma.
Hashim Abdalla MS; Taylor-Robinson SD; Sharif AW; Williams HR; Crossey MM; Badra GA; Thillainayagam AV; Bansi DS; Thomas HC; Waked IA; Khan SA
HPB (Oxford); 2011 Jun; 13(6):385-90. PubMed ID: 21609370
[TBL] [Abstract][Full Text] [Related]
13. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
[TBL] [Abstract][Full Text] [Related]
14. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Chen LX; Zou SJ; Li D; Zhou JY; Cheng ZT; Zhao J; Zhu YL; Kuang D; Zhu XH
World J Gastroenterol; 2020 Dec; 26(48):7664-7678. PubMed ID: 33505143
[TBL] [Abstract][Full Text] [Related]
16. Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study.
Navaneethan U; Lourdusamy V; Gk Venkatesh P; Willard B; Sanaka MR; Parsi MA
Gastroenterol Rep (Oxf); 2015 May; 3(2):136-43. PubMed ID: 25304323
[TBL] [Abstract][Full Text] [Related]
17. Volatile Organic Compounds in Urine for Noninvasive Diagnosis of Malignant Biliary Strictures: A Pilot Study.
Navaneethan U; Parsi MA; Lourdusamy D; Grove D; Sanaka MR; Hammel JP; Vargo JJ; Dweik RA
Dig Dis Sci; 2015 Jul; 60(7):2150-7. PubMed ID: 25708900
[TBL] [Abstract][Full Text] [Related]
18. Urinary Metabolites Diagnostic and Prognostic of Intrahepatic Cholangiocarcinoma.
Haznadar M; Diehl CM; Parker AL; Krausz KW; Bowman ED; Rabibhadana S; Forgues M; Bhudhisawasdi V; Gonzalez FJ; Mahidol C; Budhu A; Wang XW; Ruchirawat M; Harris CC
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1704-1711. PubMed ID: 31358519
[TBL] [Abstract][Full Text] [Related]
19. Urine proteomics study reveals potential biomarkers for the differential diagnosis of cholangiocarcinoma and periductal fibrosis.
Duangkumpha K; Stoll T; Phetcharaburanin J; Yongvanit P; Thanan R; Techasen A; Namwat N; Khuntikeo N; Chamadol N; Roytrakul S; Mulvenna J; Mohamed A; Shah AK; Hill MM; Loilome W
PLoS One; 2019; 14(8):e0221024. PubMed ID: 31425520
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
